Rohan Halder retweeted
NPM1 mutations are considered good risk in AML, but variant allele frequency (VAF) matters!
A VAF > 31.44% suggests that the mutation has a wide clonal penetrance, making the AML more chemo-sensitive with greater chance of cure with intensive treatment
However, if VAF < 31.44%, then the mutation is not in the predominant clone, and usually some other mutation or mutations are at play that will mediate future relapse ashpublications.org/blood/ar…
Rohan Halder retweeted
Does myeloma maintenance need to continue indefinitely?
I spoke with @AJMC_Journal's Maggie Shaw about ENDURANCE, lenalidomide maintenance and balancing disease control with toxicity, quality of life & MRD-guided care.
It's not just about living longer, but living better.
ajmc.com/view/prerna-mewawal…
#mmsm
Rohan Halder retweeted
Yes, the #Hennur - Bagalur road is in shambles. The GBA / BWSSB / Panchayat all need to immediately take this up. People are just suffering
@GBA_office @BECCUPDATES @BNCCofficial
Thx - @naveenmzs
Rohan Halder retweeted
Great work indeed.
Thanks to the @RGCI_RC and @narendra_ag1 sir led PICC program, we have trained nursing staff doing fabulous job of PICC insertion in remote places like Rajkot. Highly indebted to them.
Dr Narendra Agrawal sir has silently trained thousands of nursing and other doctors over years, who have visited from India and other countries, and has contributed to the cancer care.
In hemato-oncology, finding the right vein is clinical skill, and making vascular access safer is science! 🩸
Pleased to have contributed to this study of a nurse-led PICC program involving 1,026 patients.
Read: link.springer.com/article/10…
#Hematology #HematoOncology
Rohan Halder retweeted
It’s a government and law enforcement responsibility what’s get into the market .
Not the hospital or doctors.
Do you think it’s hospital or doctor job to test individual drugs before administering each patient. ??
Why do you have an FDA and government for ?
You don’t blame a car company for an accident driving their car on a bad road.
We have to get the responsibility part straight otherwise you will never get your answers. Extremely sorry for your loss.
We have always asked for cheaper drugs in India. And never for high quality drugs. We get what we ask for.
unavailable
Rohan Halder retweeted
Details of the appropriately named ENDURANCE trial below.
First randomization showed KRd (expensive) is not better than VRd
Second randomization showed indefinite maintenance (very expensive) not better than limited duration maintenance.
The type of trial that’s possible jnkt through the NCTN groups @theNCI in the US.
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.1056/NE…
Rohan Halder retweeted
Celebrating our @NEJM paper that showed that 2 years of lenalidomide maintenance is sufficient in myeloma. A 15 year journey. The results of this trial will in my opinion save over a billion dollars a year for Medicare.
@myelomaMD as the PI worked tirelessly and I’m so fortunate to have him as a dear friend and colleague. @eaonc @theNCI
Rohan Halder retweeted
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.1056/NE…
Rohan Halder retweeted
The selection of CML Papers for June is now available. From the many CML papers published in June, Professor Timothy Hughes has selected interesting clinical, scientific, pediatric and LMIC publications.
📖 Explore the full list of papers on our website: buff.ly/VVned53
Rohan Halder retweeted
With Tal-Dara published and concerns about ataxia/ balance disorders lets take a deep dive on GPRC5D ataxia syndrome
-> The first report of a cerebellar syndrome from GPRC5D came from MCARH019 reported by Mailankody et al
-2/17 (12%) Grd 3 cerebellar syndrome
-6.5 and 8.4 mo's after infusion
-was a DLT at 450*10^6
Rohan Halder retweeted
We did our best to make as fair a comparison as possible in @BrJHaem onlinelibrary.wiley.com/doi/…
Rohan Halder retweeted
3/ @ASCO #ASCO26 #myeloma #mmsm
- Impact of 5-Year Sustained MRD negativity in FORTE
asco.org/abstracts-presentat…
- cfDNA WGS vs Mass Spec
asco.org/abstracts-presentat…
And one bonus thought-provoking on differences in access to CARTs
asco.org/abstracts-presentat…
Rohan Halder retweeted
Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia
Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat
Rohan Halder retweeted
Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat
Rohan Halder retweeted
Not all wins are measured in survival curves, some are felt in everyday life.
@dbhurani @Rohanhematdoc @narendra_ag1
#Thalassemia #HRQoL #Hemoglobin @MoHFW_INDIA
Rohan Halder retweeted
First Indian study to directly compare dasatinib de-escalation vs upfront low-dose strategy in newly diagnosed chronic-phase CML patients, addressing a major gap in real-world Indian data.
#CML #de_escalation
@dbhurani @SujayRainchwar @Rohanhematdoc @narendra_ag1 @leukemia
Rohan Halder retweeted
What's going to be different with the new IMWG response criteria?
Main changes:
- FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone)
- No more sCR
- Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing.
- 24-hour urine at baseline, and if M-protein present, retest only to confirm CR
- Patients can be considered to have PD if they meet criteria by a variable not considered measurable at baseline (major weakness with current response criteria is that it misses light chain escape).
Next, imaging....


































